1931.HK stock down 14.44% intraday on 28 Jan 2026: watch HK$1.40 support
1931.HK stock dropped sharply intraday on 28 Jan 2026, falling 14.44% to HK$1.60 on the HKSE as volume spiked to 21,465,000.00 shares. The sell-off pushed the price to a day low of HK$1.40 and left the stock trading well below its 50-day average of HK$3.76 and 200-day average of HK$5.04. Traders flag the name-change announcement and weak technicals as drivers for today’s move, while fundamentals show a low PB of 0.67 and PE of 13.33, keeping the company on value screens.
Intraday price move and news drivers
IVD Medical Holding Limited (1931.HK) opened at HK$1.87 and hit a day low of HK$1.40 on heavy volume 21,465,000.00. The intraday drop of -14.44% follows a recent company update on its English short name change to ETHK Labs Inc., noted in market reports and linked investor commentary source. Market reaction appears amplified by outsized selling versus the stock’s average volume of 3,054,760.00.
Technical snapshot for 1931.HK stock
Short-term technicals show oversold conditions: RSI 24.99 and ADX 47.03, indicating a strong downtrend. Key intraday support is HK$1.40 and immediate resistance sits at HK$1.87. The 50-day moving average at HK$3.76 acts as a medium-term resistance. Momentum indicators suggest a quick bounce is possible, but the Bollinger lower band near HK$1.53 and ATR 0.40 imply continued volatility.
Fundamentals and valuation context
IVD Medical (1931.HK) trades at PE 13.33 with EPS HK$0.12 and market cap HK$2,594,384,000.00. The company’s price-to-book ratio is 0.67, below the Hong Kong healthcare sector average PE 29.38, signaling relative valuation support. Working capital is healthy with a current ratio 1.79, but inventory days are elevated at 478.32, which raises cash cycle concerns.
Sector comparison and risk factors
Within the Hong Kong Healthcare sector, 1931.HK stock shows lower PE and PB ratios than peers, which can appear attractive on value grounds. Main risks include a long cash conversion cycle, higher net debt to EBITDA 3.10, and market sensitivity to corporate naming or governance updates. Regulatory and demand shifts in Mainland China remain primary macro risks for medical distributors.
Meyka AI rating, forecast and price guidance
Meyka AI rates 1931.HK with a score out of 100: the stock scores 65.36 (Grade B) with a HOLD suggestion. This grade factors S&P 500 and sector comparisons, financial growth, metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a monthly price of HK$2.38 and a yearly target of HK$8.19. Versus the current price HK$1.60, the model implies a 48.75% upside to the monthly forecast and 411.68% upside to the yearly forecast. Forecasts are model-based projections and not guarantees.
Trading signals and strategy for top losers
As a top loser intraday, 1931.HK stock shows high relative volume 7.03 and an OBV trending lower, signalling distribution. Short-term traders can watch a recovery above HK$1.87 for a scalp, while value investors should monitor inventory reduction and operating cash flow recovery. Use tight stops: a break below HK$1.40 would likely extend downside toward the 52-week low HK$1.40.
Final Thoughts
Today’s intraday drop makes 1931.HK stock one of the HKSE top losers on 28 Jan 2026, with price at HK$1.60 and volume 21,465,000.00 amplifying the move. The combination of a low PB 0.67, PE 13.33, and a healthy current ratio 1.79 argues for underlying value, but elevated inventory days 478.32 and net debt to EBITDA 3.10 keep near-term risks high. Meyka AI’s models place a nearer-term projection at HK$2.38 (≈48.75% upside) and a year target at HK$8.19 (≈411.68% upside) versus today’s price HK$1.60. These figures illustrate the gap between market pricing and model expectations; forecasts are model-based projections and not guarantees. Traders should weigh technical signals, confirm operational improvements, and consult the company’s upcoming earnings on 2026-03-13 before increasing exposure. For live quote tracking and intraday alerts, see our Meyka stock page for 1931.HK Meyka stock page. For more context on the name-change and market reaction, read the coverage source.
FAQs
Why did 1931.HK stock fall sharply intraday today?
1931.HK stock fell 14.44% intraday after heavy selling tied to a corporate English name-change announcement and technical weakness. Volume spiked to 21,465,000.00. Market sentiment and stretched inventory metrics likely amplified the move.
What are the key support and resistance levels for 1931.HK stock?
Key intraday support is HK$1.40 and resistance is the open at HK$1.87. Watch the 50-day MA HK$3.76 as medium-term resistance if the stock stages a recovery.
How does Meyka AI view 1931.HK stock and what are the forecasts?
Meyka AI rates 1931.HK 65.36/100 (Grade B, HOLD). Meyka AI’s forecast model projects HK$2.38 monthly and HK$8.19 yearly; forecasts are projections and not guarantees.
Is 1931.HK stock cheap compared with its sector?
On valuation, 1931.HK stock trades at PE 13.33 and PB 0.67, below the Healthcare sector average PE 29.38, suggesting relative cheapness. Elevated inventory days and cash conversion risks offset that view.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
